TG Therapeutics
TGTX
75 hedge funds and large institutions have $296M invested in TG Therapeutics in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 10 closing their positions.
260% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 10
212% more call options, than puts
Call options by funds: $9.62M | Put options by funds: $3.09M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
79% more capital invested
Capital invested by funds: $165M → $296M (+$131M)
14% more funds holding
Funds holding: 66 → 75 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.7M |
| 3 |
HH
HWG Holdings
Houston,
Texas
|
+$4.81M |
| 4 |
VAM
Visium Asset Management
New York
|
+$4.68M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$23.6M |
| 2 |
JP Morgan Chase
New York
|
-$10.8M |
| 3 |
Jennison Associates
New York
|
-$4.37M |
| 4 |
CCI
Columbus Circle Investors
|
-$2.97M |
| 5 |
Millennium Management
New York
|
-$1.46M |
TGTX Hedge Fund Activity: Q4 2014 in Review
75 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2014, worth a combined $296M — up 79% from $165M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TGTX positions and 10 closed out — a net gain of 10 holders — while 36 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $25.1M. The largest seller was Bridger Management, cutting an estimated $23.6M.
- 75 institutional investors held TG Therapeutics (TGTX) as of Q4 2014, up from 66 in Q3 2014.
- Funds reported $296M of TG Therapeutics stock for Q4 2014, up 79% quarter-over-quarter.
- 20 funds opened new TG Therapeutics positions in Q4 2014 and 10 closed out, a net change of +10 holders.
- The largest TG Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $25.1M added.
- The largest TG Therapeutics seller in Q4 2014 was Bridger Management, an estimated $23.6M sold.
Based on aggregated 13F filings for Q4 2014.